Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

COVID-19 poses threat for cirrhotics

24 Oct 2020

In cirrhotic patients, the novel coronavirus disease (COVID-19) is linked to the deterioration of liver function and greater mortality, a new study has found.

Researchers conducted a multicentre retrospective analysis on 50 cirrhotic patients (median age, 67 years; 70 percent male) with SARS-CoV-2 infection, as confirmed by reverse-transcriptase polymerase chain reaction.

Compared with either the last outpatient visit or with a blood test prior to admission, liver parameters had changed at COVID-19 diagnosis. For instance, bilirubin (p=0.026), creatinine (p=0.007), international normalized ratio (p=0.042), and alanine aminotransferase (ALT; p=0.024) all significantly increased. Albumin concentrations, on the other hand, decreased (p=0.0003).

These changes influenced scores on the Model for End-Stage Liver Disease (MELD), such that the percentage of patients with score ≥15 doubled from 13 percent to 26 percent (p=0.037). Almost half of the patients decompensated.

Ten patients (45 percent) developed acute liver injuries despite having persistently normal ALT levels, and six patients (12 percent) experienced a hepatitis flare. There were no instances of upper gastrointestinal bleeding.

Seventeen patients died from SARS-CoV-2 infection, yielding a 34-percent 30-day cumulative probability of overall mortality. In most of these deaths (71 percent; n=12), COVID-19 with respiratory failure was considered the cause, while end-stage liver disease was the principal reason for mortality in the remaining five deaths.

Multivariate analysis found that moderate/severe lung failure was a significant predictor of mortality (hazard ratio [HR], 1.950, 95 percent confidence interval [CI], 1.279–2.974; p=0.002), as was the MELD score (HR, 1.094, 95 percent CI, 1.047–1.144; p≤0.0001).

“[A]s the current pandemic of SARS-CoV-2 is spreading, physicians and hepatologists should be aware of the potential detrimental effects of this infection on the short-term outcome of such a fragile patient population as cirrhotics,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.